Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to PDGF-B. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of PDGF-B mediated diseases, disorders or conditions.

Abstract: A process for producing ethylene glycol includes contacting an oxalate with a fluidized bed catalyst under the following conditions: a reaction temperature of from about 170 to about 270° C., a weight space velocity of oxalate of from about 0.2 to about 7 hours?1, a hydrogen/ester molar ratio of about 20˜200:1, a reaction pressure of from about 1.5 to about 10 MPa, and a reaction temperature difference T of from about 1 to about 15° C. The fluidized bed catalyst includes: a) from about 5 to about 80 parts by weight of copper and the oxide thereof, b) from about 10 to about 90 parts by weight of at least one carrier selected from silica, molecular sieve or alumina, c) from about 0.01 to about 30 parts by weight of bismuth and tungsten metallic elements or the oxides thereof, or cerium and niobium metallic elements or the oxides thereof.

Abstract: The present invention discloses a process for the selective hydrogenation of phenylacetylene in the presence of styrene conducted in a combined bed, which process comprises under hydrogenation reaction conditions, passing a hydrocarbon fraction feedstock containing phenylacetylene and styrene through a combined bed reactor containing a catalyst A and a catalyst B to contact the feedstock with the catalyst A and the catalyst B in turn, wherein the catalyst A is a nickel-based catalyst, the catalyst B is at least one selected from the group consisting of palladium-based catalysts and copper-based catalysts, and a weight ratio of the catalyst A loaded to the catalyst B loaded is from 0.5:1 to 5:1.

Abstract: The present invention relates to a process of producing oxalate by CO gas phase method for chiefly solving the technical problem of the low utilization efficiency of nitrogen oxides or nitrous acid esters in the prior art.

Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to PDGF-B. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of PDGF-B mediated diseases, disorders or conditions.

Abstract: A process for producing ethylene glycol includes contacting an oxalate with a fluidized bed catalyst under the following conditions: a reaction temperature of from about 170 to about 270° C., a weight space velocity of oxalate of from about 0.2 to about 7 hours?1, a hydrogen/ester molar ratio of about 20˜200:1, a reaction pressure of from about 1.5 to about 10 MPa, and a reaction temperature difference T of from about 1 to about 15° C. The fluidized bed catalyst includes: a) from about 5 to about 80 parts by weight of copper and the oxide thereof, b) from about 10 to about 90 parts by weight of at least one carrier selected from silica, molecular sieve or alumina, c) from about 0.01 to about 30 parts by weight of bismuth and tungsten metallic elements or the oxides thereof, or cerium and niobium metallic elements or the oxides thereof.

Abstract: A process for selective oxidative dehydrogenation of a hydrogen-containing CO mixed gas, comprising contacting a hydrogen-containing CO mixed gas raw material with at least one catalyst entity having an increased activity gradient disposed in a reactor under at least one reaction condition chosen from a reaction temperature ranging from 100 to 300° C., a volume space velocity ranging from 100 to 10000 h?1, and a reaction pressure ranging from ?0.08 to 5.0 MPa, wherein the molar ratio of oxygen to hydrogen in the raw material ranges from 0.5:1 to 5:1.

Abstract: The present invention relates to a process of producing oxalate by CO gas phase method for chiefly solving the technical problem of the low utilization efficiency of nitrogen oxides or nitrous acid esters in the prior art.

Abstract: The present invention discloses a process for the selective hydrogenation of phenylacetylene in the presence of styrene conducted in a combined bed, which process comprises under hydrogenation reaction conditions, passing a hydrocarbon fraction feedstock containing phenylacetylene and styrene through a combined bed reactor containing a catalyst A and a catalyst B to contact the feedstock with the catalyst A and the catalyst B in turn, wherein the catalyst A is a nickel-based catalyst, the catalyst B is at least one selected from the group consisting of palladium-based catalysts and copper-based catalysts, and a weight ratio of the catalyst A loaded to the catalyst B loaded is from 0.5:1 to 5:1.

Abstract: A process for selective oxidative dehydrogenation of a hydrogen-containing CO mixed gas, comprising contacting a hydrogen-containing CO mixed gas raw material with at least one catalyst entity having an increased activity gradient disposed in a reactor under at least one reaction condition chosen from a reaction temperature ranging from 100 to 300° C., a volume space velocity ranging from 100 to 10000 h?1, and a reaction pressure ranging from ?0.08 to 5.0 MPa, wherein the molar ratio of oxygen to hydrogen in the raw material ranges from 0.5:1 to 5:1.

Abstract: The present invention provides methods of treating inflammatory diseases/disorders in a subject by inhibiting/antagonizing TREM-1 expression/activity/signal transduction and/or DAP12/TyroBP expression and/or activity. Methods of detecting the presence of inflammatory disease in a subject by detecting TREM-1 and/or DAP12/TyroBP expression and/or activity in the subject or a sample obtained therefrom, wherein increased expression or activity is indicative of the inflammatory disease are also included. The present invention further provides methods for assessing the efficacy of a TREM-1-modulating agent administered to a patient by detecting levels of secreted phosphoprotein 1 (SPP1) and/or one or more other biomarkers in the patient or in a sample from the patient.

Abstract: The invention relates to compositions and methods comprising lymphotoxin-beta receptor (LT?R) modulators, which activate or inhibit LT?R signaling. LT?R modulators are useful for treating lymphocyte mediated immunological diseases and cancer, and more particularly, for regulating mitochondrial-mediated apoptosis. This invention relates to soluble forms of the LT?R complex proteins that act as LT?R activating or inhibiting agents. This invention also relates to the use of soluble molecules, directed against either the LT?R, its ligands, LIGHT and LT?1?2, or its intracellular binding partners, that function to regulate LT?R signaling. A novel screening method for selecting soluble receptors, antibodies and other agents that modulate LT?R signaling is provided.

Abstract: The invention relates to compositions and methods comprising lymphotoxin-beta receptor (LT?R) modulators, which activate or inhibit LT?R signaling. LT?R modulators are useful for treating lymphocyte mediated immunological diseases and cancer, and more particularly, for regulating mitochondrial-mediated apoptosis. This invention relates to soluble forms of the LT?R complex proteins that act as LT?R activating or inhibiting agents. This invention also relates to the use of soluble molecules, directed against either the LT?R, its ligands, LIGHT and LT?1?2, or its intracellular binding partners, that function to regulate LT?R signaling. A novel screening method for selecting soluble receptors, antibodies and other agents that modulate LT?R signaling is provided.

Abstract: The present invention relates to, among other embodiments, protein complexes which include tumor necrosis factor alpha (TNF-?) and/or tumor necrosis factor alpha receptor (TNFR). Preferably, the complexes comprise at least one polypeptide selected from the group consisting of: NF-?B activating kinase (NAK), RasGAP3, TRCP1, and TRCP2. The present invention further provides assays of identifying a compound for modulating the stability and activity of the complex. Also provided are methods of modulating apoptosis and inflammation, as well as treating TNF-? related diseases.

Abstract: The invention relates to compositions and methods comprising lymphotoxin-beta receptor (LT&bgr;R) modulators, which activate or inhibit LT&bgr;R signaling. LT&bgr;R modulators are useful for treating lymphocyte mediated immunological diseases and cancer, and more particularly, for regulating mitochondrial-mediated apoptosis. This invention relates to soluble forms of the LT&bgr;R complex proteins that act as LT&bgr;R activating or inhibiting agents. This invention also relates to the use of soluble molecules, directed against either the LT&bgr;R, its ligands, LIGHT and LT&bgr;1&agr;2, or its intracellular binding partners, that function to regulate LT&bgr;R signaling. A novel screening method for selecting soluble receptors, antibodies and other agents that modulate LT&bgr;R signaling is provided.